论文部分内容阅读
目的:研究分析人尿激肽原酶对缺血区脑灌注的影响和机制。方法:选取在我院采用缺血区脑灌注进行治疗的120例脑梗死患者,将患者随机分成实验组和对照组,平均每组60例患者,对照组的患者采用静滴丹参川芎嗪和奥扎格雷钠治疗,实验组的患者采用静滴丹参川芎嗪和人尿激肽原酶(尤瑞克林)治疗。观察两组患者在治疗前后的神经细胞功能的情况及治疗后的临床疗效。结果:治疗后,实验组患者的NIHSS评分和m RS指数均明显低于对照组的患者,在统计学上有意义(P<0.05);实验组患者的总有效率(91.67%)明显高于对照组患者的总有效率(66.67%),在统计学上有意义(P<0.05)。结论:对于采用缺血区脑灌注的患者同时给予人尿激肽原酶治疗,可以使患者的脑缺血再灌注损伤得到保护,使神经细胞凋亡减轻,可以有效的使缺血脑组织能量和供氧效果得到改善,使脑缺血后的血管再生效果得到促进,对脑梗死患者的治疗有显著的临床疗效。
Objective: To study the effect and mechanism of human urokinase on cerebral perfusion in ischemic area. Methods: A total of 120 patients with cerebral infarction who were treated with ischemic cerebral perfusion in our hospital were randomly divided into experimental group and control group, with an average of 60 patients in each group. Patients in the control group were treated with intravenous infusion of Salviae Miltiorrhizae Zagre sodium treatment, the experimental group of patients with intravenous infusion of Salvia Ligustrazine and human urokinase (Urelin) treatment. To observe the function of nerve cells in both groups before and after treatment and the clinical effect after treatment. Results: After treatment, the NIHSS score and mRSR of the experimental group were significantly lower than those of the control group (P <0.05). The total effective rate (91.67%) in the experimental group was significantly higher than that of the control group The total effective rate of patients in the control group (66.67%) was statistically significant (P <0.05). Conclusion: The simultaneous administration of human kininogenase in patients with ischemic cerebral perfusion can protect patients from cerebral ischemia-reperfusion injury and reduce the apoptosis of nerve cells, which can effectively reduce the energy of ischemic brain tissue And the oxygen effect is improved, so that the effect of blood vessel regeneration after cerebral ischemia is promoted, and there is a significant clinical effect on the treatment of patients with cerebral infarction.